Bevacizumab, the first anti-angiogenesis agent approved for glioma, neutralizing VEGF, prolongs progression-free survival (PFS) in GBM patient, however, showed minimal efficacy for overall survival (OS) [2]. This evidence concerns the gene VEGFA and central nervous system cancer.